Cadila Healthcare, a global pharmaceutical company, and Zydus Pharmaceuticals (USA, a leading generic pharmaceutical company in the United States, announced that they have entered into a settlement and license agreement with Somaxon Pharmaceuticals, and ProCom One to resolve pending patent litigation involving Silenor (Doxepin) 3 mg and 6 mg tablets.

Under the settlement and license agreement, Cadila Healthcare (Q,N,C,F)* and Zydus Pharmaceuticals (USA), have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United States under a license from Somaxon, 180 days after a United States court enters a final decision that Somaxon`s patents are not infringed, invalid or unenforceable, or earlier under certain circumstances.

Shares of the company gained Rs 7.15, or 0.82%, to settle at Rs 879.65. The total volume of shares traded was 48,199 at the BSE (Thursday).